Stella Diagnostics (Stella Diagnostics) Interest Income : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Stella Diagnostics's interest income for the three months ended in Sep. 2023 was $0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Stella Diagnostics Interest Income Historical Data

The historical data trend for Stella Diagnostics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Interest Income Chart

Stella Diagnostics Annual Data

Trend

Interest Income

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Interest Income	-	-

Stella Diagnostics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.